PART I Overview We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Our ...
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-11 | 2025-12-31 | 0001104659-26-026140 | EDGAR | 107K words |
| 2025-03-12 | 2024-12-31 | 0001558370-25-002747 | EDGAR | — |
| 2024-03-25 | 2023-12-31 | 0001558370-24-003812 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001193125-26-343441 | EDGAR | — |
| 2025-11-13 | 2025-09-30 | 0001104659-25-110846 | EDGAR | 20K words |
| 2025-08-13 | 2025-06-30 | 0001558370-25-011301 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001558370-25-006836 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001558370-24-015623 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001558370-24-012136 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001558370-24-008205 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001558370-23-018700 | EDGAR | — |
| 2023-08-21 | 2023-06-30 | 0001104659-23-093910 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-13 | 0001193125-26-347854 | EDGAR | — |
| 2026-08-11 | 0001193125-26-343446 | EDGAR | — |
| 2026-07-21 | 0001193125-26-309334 | EDGAR | — |
| 2026-03-11 | 0001104659-26-026146 | EDGAR | 7K words |
| 2026-02-02 | 0001104659-26-008925 | EDGAR | — |
| 2025-12-18 | 0001104659-25-122272 | EDGAR | — |
| 2025-12-17 | 0001104659-25-121819 | EDGAR | — |
| 2025-11-13 | 0001104659-25-110852 | EDGAR | — |
| 2025-10-23 | 0001104659-25-101819 | EDGAR | — |
| 2025-08-22 | 0001104659-25-081630 | EDGAR | — |
67 total filings indexed. 45 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001400118 |
| Ticker | SGMT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.sagimet.com |
| Listed | 2023-07-14 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/SGMT (~200 tokens, structured JSON with cryptographic provenance)